Development and validation of a novel nomogram incorporating psychosocial factors for predicting hypoglycemia during perioperative period of digestive endoscopy (DREAM-Hypo Model)

开发和验证一种纳入社会心理因素的新型列线图,用于预测消化内镜手术围手术期低血糖(DREAM-Hypo 模型)

阅读:1

Abstract

BACKGROUND: Perioperative hypoglycemia during digestive endoscopy poses significant risks, with reported incidence rates of 6.75-18.70%. Traditional models focus on metabolic factors, while psychosocial stressors (anxiety, poor sleep quality) may exacerbate risk through neuroendocrine dysregulation. This study aims to develop a novel nomogram (DREAM-Hypo Model) integrating psychosocial, clinical, and metabolic predictors for hypoglycemia risk stratification. METHODS: We prospectively enrolled 610 patients undergoing therapeutic digestive endoscopy at The First Affiliated Hospital of Ningbo University, China (Jan-Jun 2024). Participants were randomly allocated to training and validation cohorts (7:3 ratio). Predictors were identified via univariate and multivariate logistic regression. Model performance was assessed using ROC curves, calibration plots, and decision curve analysis (DCA), with internal validation via 500 bootstrap resamples. METHODS: We prospectively enrolled 610 patients undergoing therapeutic digestive endoscopy at The First Affiliated Hospital of Ningbo University, China (Jan-Jun 2024). Participants were randomly allocated to training and validation cohorts (7:3 ratio). Predictors were identified via univariate and multivariate logistic regression. Model performance was assessed using ROC curves, calibration plots, and decision curve analysis (DCA), with internal validation via 500 bootstrap resamples. RESULTS: The overall hypoglycemia incidence was 14.92%. Six independent predictors were identified: fasting time, anxiety, sleep quality, male gender, diabetes, and somatostatin use (all p<0.05). The nomogram showed strong discrimination (training cohort AUC: 0.830, 95% CI: 0.795-0.865; validation cohort AUC: 0.809, 95% CI: 0.752-0.866). DCA confirmed clinical utility, with superior net benefits at thresholds of 25-30%. CONCLUSION: The DREAM-Hypo nomogram effectively integrates metabolic, procedural, and psychosocial factors to predict perioperative hypoglycemia risk, supporting individualized risk stratification and targeted interventions. TRIAL REGISTRATION: ClinicalTrials.gov, NCT07132476. Registered on August 19, 2025.National Medical Research Registration and Filing Information System, MR-3-25-035244. Registered on May 7, 2025.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。